First Patients Recruited In The Extended Phase III Programme Using Lu AA21004 In MDD

First Patients Recruited In The Extended Phase III Programme Using Lu AA21004 In MDD
H. Lundbeck A/S (Lundbeck) announced that the first patients have been recruited and dosed in the new phase III programme using Lu AA21004 in major depression (MDD). The first patients have been recruited in Finland. As previously communicated filing of Lu AA21004 is anticipated in 2012. The extended phase III programme for Lu AA21004 is based on clinical data obtained until now…

Read more on Medical News Today

How To Transform Current Pharma Quality Issues Into Next Business Opportunities?

How To Transform Current Pharma Quality Issues Into Next Business Opportunities?
For three September days, Lisbon, Portugal will become the capital city of Pharma Quality professionals. Senior level executives from Europe and World leading companies will meet at a conference aimed to discuss the ideal practices on how to achieve QC work excellence, how and where to deploy and develop measurable calibre systems, Quality Risk Management, QbD & PAT and much more… We …

Read more on Medical News Today

Lytix Biopharma As Update On Phase I Progress With OncoporeTM For Solid Tumours

Lytix Biopharma As Update On Phase I Progress With OncoporeTM For Solid Tumours
The Norwegian pharmaceutical company Lytix Biopharma AS provided an update at the current BIO conference in Chicago on Phase I clinical trials of OncoporeTM (LTX-315) for the treatment of cancer. During a session hosted by the European Cancer Cluster (Norwegian Oslo Cancer Cluster and French Cancer-Bio-Santé Cluster) at the current BIO conference in Chicago, Head of Lytix Biopharma Business …

Read more on Medical News Today

As Collaborations Grow Between Developing Countries’ Biotech Firms Cheaper Drugs, Vaccines Forecast

As Collaborations Grow Between Developing Countries’ Biotech Firms Cheaper Drugs, Vaccines Forecast
The availability of more inexpensive drugs, vaccines and diagnostics that would help countless people worldwide is the foremost benefit expected from a growing number of collaborations between biotech firms in developing countries, according to a study to be published Mon. Might 10 in the UK journal Nature Biotechnology…

Read more on Medical News Today

Probiotic Invention Helps Prevent Lactose Intolerance Symptoms

Probiotic Invention Helps Prevent Lactose Intolerance Symptoms
Ganeden Biotech announced that it was allowed a patent by the United Says Patent and Trademark Office for its invention utilizing a combination of probiotics and disaccharidase to increase disaccharide digestion in people with disaccharide intolerance. Lactose intolerance , or the inability to digest lactose, impacts up to 50 million Americans, plaguing sufferers with diarrhea, gas, and/or bloating after they …

Read more on Medical News Today

Next Page »